Deoxynivalenol (Vomitoxin)-Induced Cholecystokinin and Glucagon-Like Peptide-1 Release in the STC-1 Enteroendocrine Cell Model Is Mediated by Calcium-Sensing Receptor and Transient Receptor Potential Ankyrin-1 Channel

Hui-Ren Zhou* and James J. Pestka*,†,‡,1

*Department of Food Science and Human Nutrition, †Department of Microbiology and Molecular Genetics and ‡Center for Integrative Toxicology, Michigan State University, East Lansing, Michigan 48824

1To whom correspondence should be addressed at 234 G.M. Trout Building, Michigan State University, East Lansing, MI 48824-1224. Fax: (517) 353-8963. E-mail: pestka@msu.edu.

ABSTRACT

Food refusal is a hallmark of exposure of experimental animals to the trichothecene mycotoxin deoxynivalenol (DON), a common foodborne contaminant. Although studies in the mouse suggest that DON suppresses food intake by aberrantly inducing the release of satiety hormones from enteroendocrine cells (EECs) found in the gut epithelium, the underlying mechanisms for this effect are not understood. To address this gap, we employed the murine neuroendocrine tumor STC-1 cell line, a widely used EEC model, to test the hypothesis that DON-induced hormone exocytosis is mediated by G protein-coupled receptor (GPCR)-mediated Ca2+ signaling. The results indicate for the first time that DON elicits Ca2+-dependent secretion of cholecystokinin (CCK) and glucagon-like peptide-17-36 amide (GLP-1), hormones that regulate food intake and energy homeostasis and that are products of 2 critical EEC populations—I cells of the small intestine and L cells of the large intestine, respectively. Furthermore, these effects were mediated by the GPCR Ca2+-sensing receptor (CaSR) and involved the following serial events: (1) PLC-mediated activation of the IP3 receptor and mobilization of intracellular Ca2+ stores, (2) activation of transient receptor potential melastatin-5 ion channel and resultant L-type voltage-sensitive Ca2+ channel-facilitated extracellular Ca2+ entry, (3) amplification of extracellular Ca2+ entry by transient receptor potential ankyrin-1 channel activation, and finally (4) Ca2+-driven CCK and GLP-1 exocytosis. These in vitro findings provide a foundation for future investigation of mechanisms by which DON and other trichothecenes modulate EEC function in ex vivo and in vivo models.

Key words: mycotoxin; deoxynivalenol; CaSR; TRPA1; CCK; GLP-1

Deoxynivalenol (DON or vomitoxin) is a trichothecene mycotoxin produced by the fungus Fusarium graminearum following infestation of cereal grains in the field or during storage (Pestka, 2010). Frequently detected in wheat, barley, and corn, DON elicits a range of acute and chronic adverse effects in experimental animals that include anorexia, nausea, emesis, neuroendocrine changes, growth suppression, weight loss, and immunotoxicity (Maresca, 2013). DON’s capacity to evoke anorectic responses and consequent potential to interfere with growth of children and young animals are critical concerns from a public health perspective. These adverse effects were the basis for determining the tolerable daily intake for DON (Canady et al., 2001) that has been used to define regulatory limits for this mycotoxin in food (EFSA, 2013).
Appetite and food intake are normally controlled by both central and peripheral factors that influence the balance of anor exogenic and orexigenic signaling in the brain (Schwartz, 2006). In the mouse, oral exposure to DON rapidly upregulates the expression of specific components of the anorexigenic response in hypothalamic neurons of the brain, including the pro-opiomelanocortin (POMC), melanocortin 4 receptor (MC4R), and cocaine amphetamine-regulated transcript (Girardet et al., 2011a,b). A potential upstream mechanism for elevated expression of these hypothalamic anorexigenic hormones is increased secretion of the gut satiety peptides by enteroendocrine cells (EEC) of the gastrointestinal (GI) tract (Moran-Ramos et al., 2012; Steinert et al., 2013).

The EEC is a primary intestinal cell subtype that, along with enterocytes, goblet, and Paneth cells derived from intestinal stem cells populates the epithelial layer of the GI tract (Moran-Ramos et al., 2012). Although EECs comprise only ~1% of all gut epithelial cells, as a whole they represent one of the largest endocrine organs in the body, making them a central target for toxins entering the gut. At least 15 regionally associated EEC lineages have been described that are generated from a common neurogenin3-positive secretory progenitor population. A paramount function of EECs is to sense nutrients of the gut lumen and respond by secreting a range of peptide and amine hormones. These hormones control numerous digestive and physiologic functions, including food intake, postmeal gastric secretion, gut motility, energy expenditure, and maintenance of glucose levels by acting peripherally on adjacent cells and afferent enteric neurons and/or on distal cells of the central nervous system (Gribble, 2012; Reimann et al., 2012; Tolhurst et al., 2012).

Cholecystokinin (CCK), peptide YY₃-₃₆ (PYY₃-₃₆), and glucagon-like peptide-₁₇-₃₆ amide (GLP-₁) are examples of satiety hormones secreted by EEC. CCK is produced by I cells, an EEC population found in the jejunum and ileum, that elicits short-term, diminished food consumption by upregulating POMC and MC₄R expression (Dockray, 2009). Both peripheral and central administration of CCK to animals causes decreased food consumption. PYY₃-₃₆ is produced by L-cells, an EEC population that populates the lower GI tract including the distal ileum and colon (Karra and Batterham, 2010). This hormone both upregulates anorexigenic and downregulates orexigenic signaling molecules within the brain, inducing satiety in many species including humans, nonhuman primates, and rodents. GLP-₁ is another hormone of L-cell origin that is secreted in response to a meal and evokes satiety (Williams et al., 2009). Several recent investigations by our laboratory support the contention that EEC-derived gut satiety hormones contribute to DON’s anorectic effects in mice. Importantly, both oral and IP administration of DON in mice dose-dependently induces rapid (~15 min) elevations in plasma CCK and PYY₃-₃₆ with concurrent food refusal (Flannery et al., 2012; Wu et al., 2014). Subsequent experiments with specific pharmacologic antagonists to CCK and PYY receptors attenuate this effect, thus further indicating that these hormones are upstream mediators of DON-induced anorexigenic signaling in the hypothalamus.

Although in vivo studies have established that DON suppresses food intake by inducing the aberrant release of hormones originating from EEC, the upstream mechanisms for this effect are not understood. Recent investigations have demonstrated that a variety of G protein-coupled receptors (GPCRs) are present in EEC that function as chemosensors of the gut luminal content (Liou, 2013; Reimann et al., 2012). The goal of this research study was to test the hypothesis that DON induces hormone exocytosis in EEC by GPCR-mediated Ca²⁺ signaling. To achieve this goal, we employed a widely used EEC model, the murine neuroendocrine tumor STC-1 cell (Hira et al., 2008; Kurogi et al., 2012; Shah et al., 2012), that exhibits characteristics of both duodenal I-cells (ie, secretes CCK) and ileal-colonic L-cells (ie, secretes GLP-1) (Geraedts et al., 2011). Our primary focus was to determine DON’s short-term (15–45 min) effects (ie, intracellular calcium increase and hormone secretion) in this enteroendocrine model that would be indicative of an intestinal chemical defense response (eg, food refusal) observed in vivo in the mouse (Flannery et al., 2012; Wu et al., 2014). The results suggest that DON induces secretion of both hormones from STC-1 by activating the GPCR calcium-sensing receptor (CaSR) as well as a unique downstream pathway involving transient receptor potential melastatin-5 ion channel (TRPM-5) and transient receptor potential ankyrin-1 (TRPA1).

**MATERIALS AND METHODS**

Chemicals. DON (>98.00% purity) and all other chemicals were purchased from Sigma-Aldrich (St. Louis, Missouri) unless otherwise indicated. Tocris Bioscience (Minneapolis, Minnesota) was the source of EGTA, a Ca²⁺ chelator; U73122, a phospholipase C inhibitor; 2-aminoethyl diphenyl-borinate (2-APB), an IP₃ receptor antagonist; nitrendipine, a L-type voltage-sensitive Ca²⁺ channel (L-type VSCCs) blocker; triphenylphosphine oxide (TPPO), a selective inhibitor of the TRPM-5; NPS 568, a CaSR agonist; NPS 2143 and Calhex 231, CaSR antagonists; AITC, a TRPA1 agonist; and HC 00031 and A 967079, selective TRPA1 channel blockers. The concentrations for the various agonists and antagonists were selected based on supplier recommendations and preliminary experiments and were consistent with those used in previous reported cell culture studies.

Cell culture. The STC-1 cell line was kindly provided at the 25th passage by Dr Hanahan (University of California, San Francisco, California) via the ATCC culture collection (Manassas, Virginia). Cells were maintained in DMEM high glucose medium with L-glutamine, without sodium pyruvate supplemented with 10% (v/v) fetal bovine serum, 100 units/ml penicillin, and 100 μg/ml streptomycin plus 25 μg/ml gentamicin (Life Technologies, Grand Island, New York) at 37°C in 5% CO₂/air. Cells were routinely subcultured by trypsinization with 0.25% (w/v) trypsin-EDTA (Life Technologies) upon reaching 80%–90% confluence. Cells between 25 and 35 passages were used. Viability of cultures was tested by Trypan blue exclusion and MTT assay and/or Vybrant MTT Cell Proliferation Assay Kit (Life Technologies, Grand Island, New York).

**Measurement of CCK and GLP-1 release.** For determining DON’s effects on viability and hormone release, STC-1 cells were cultured in 24-well plates (2 × 10⁵ cells/well) until they reached 80%–90% confluence. Cell supernatant was removed and replaced with DON (0–5 mM) with or without antagonists dissolved in Hank’s balanced salts solution (HBSS) supplemented with 20 mM of HEPEs and additional 4.5 mM D-glucose for final glucose concentration of 10 mM and incubated for indicated time intervals. Following treatment with DON, supernatants were collected and centrifuged at 1000 x g for 5 min at 4°C to remove cells. Hormone concentrations in cell culture supernatants were measured using a CCK (26-33) (nonsulfated) EIA Kit and GLP-1 (7-36)-amide EIA Kit from Phoenix Pharmaceuticals, Inc Burlingame, California), according to the manufacturer’s recommendations.
Assessment of [Ca^{2+}]_i by confocal microscopy. STC-1 cells were grown on Basement Membrane Matrix Gel (BD Biosciences, Bedford, Massachusetts)—coated Lab-Tek II chambered cover slides (Fisher Scientific, Pittsburgh, Pennsylvania). Slides were washed with HBSS and then stained with 2 μM Fluoro-4 AM in bath solution consisting of HBSS supplemented with 20 mM of HEPES and additional 4.5 mM D-glucose for final glucose concentration of 10 mM for 30 min in dark at room temperature. Slides were then washed twice using bath solution, followed by addition of 1 ml bath solution. DON, agonists and/or antagonists were applied by pipette and then changes in intracellular Ca^{2+} were monitored using an Olympus Fluoview FV 1000 Confocal Laser Scanning Microscope (Olympus America Inc Center Valley, Pennsylvania). An Argon ion laser was used for fluorescence excitation at 488 nm. The fluorometric signals obtained were expressed as relative fluorescence change, ΔF/F₀ = (F – F₀)/ F₀, where F₀ was the basal fluorescence level. Increases in fluorescence >10% above baseline were deemed positive responses.

RT-PCR analysis for TRPM5, TRPA1, and CaSR mRNA. Total RNA was purified from adherent monolayer of STC-1 cells in a 6-well culture plate with TRI Reagent solution (Life Technologies). Resultant first-strand cDNA was used as a template for PCR. The following primer pairs were used: TRPM5: 5'-ACC TTGCCACCTGAACTGAT-3' and 5'-CCACACGGACAGCATAGGT G-3' (Staaf et al., 2010); CaSR: 5'-GAGCAGTCTCCTCCACACCACATC-3', 5'-AAGTCAATGGAAGATGCTCTT-3' (Hira et al., 2008); and TRPA1: 5'-CATGATCTACCCCTACATG-3' and 5'ACAGGTC GTCTCCCCACT TA-3' (Cattaruzza et al., 2010). PCR conditions were as follows: 1 cycle of 3 min at 94°C, 35 cycle each for 45 sec at 94°C, 30 sec at 55°C, 1 min 30 sec at 72°C and 1 cycle of 10 min at 72°C. PCR products were then separated on a 1% (w/v) agarose gel with 0.1% (w/v) ethidium bromide. PCR product sizes were 429, 320, and 216 bp for TRPM5, CaSR, and TRPA1, respectively.

Western blot analysis for TRPM5, CaSR, and TRPA1. Total proteins were extracted from adherent monolayers of STC-1 cells in a 100 μM culture plate by adding boiling lysis buffer consisting of 1% (w/v) SDS, 1 mM sodium orthovanadate and 10 mM Tris (pH 7.4). Cells were boiled in lysis buffer for 5 min, sonicated briefly and then centrifuged at 12,000 x g for 10 min at 4°C. The protein concentration of the resultant supernatant was determined with a BCA Protein Assay Kit (Thermo Scientific, Rockford, Illinois). Samples (40 μg protein) were resolved on a precast 4%–20% (w/v) polyacrylamide gel (Bio-Rad, Hercules, California) and the proteins were transferred to an Immobilon-FL membrane (Millipore, Billerica, Massachusetts). After blocking with Odyssey Blocking buffer (LI-COR, Lincoln, Nebraska) for 1 h at 25°C, membranes were incubated overnight at 4°C in LI-COR blocking buffer with goat polyclonal anti-TRPM5 (1:10,000) (NB1-44059, Novus, Littleton, Colorado); rabbit polyclonal anti-CaSR of mouse, rat, and human origin (NB1-19452, Novus) (1:1000) or rabbit polyclonal anti-TRPA1 (A688487, Abcam, Cambridge, Massachusetts) (1:10,000). Blots were washed 3 times of 10 min with TBST buffer (50 mM Tris, 150 mM NaCl and 0.1% [v/v] Tween 20, PH7.5) and then incubated in blocking buffer containing either IRDye 800CM donkey anti-goat IgG (H + L) (LI-COR) (1:20,000) for TRPM5 or IRDye 800CW goat anti-mouse IgG (H + L) secondary antibody (LI-COR) (1:3000 for CaSR or 1:20,000 for TRPA1). Infrared fluorescence intensity was detected on the Odyssey Infrared Imaging System (LI-COR).

Imunocytochemical detection of CaSR. Briefly, STC-1 cells were grown on BD Matrigel Basement Membrane Matrix coated cover glasses. These were washed with PBS once, fixed with cold methanol containing 0.3% (v/v) H2O2 for 15 min, and then washed with PBS twice. The washed cells were permeabilized with 0.1% (v/v) Triton X-100 in PBS for 10 min and washed with PBS twice. The fixed cells were blocked with 1.5% (v/v) goat serum in PBS for 30 min and then incubated with primary anti CaSR antiserum at a concentration of 10 μg/ml in 1.5% (v/v) goat serum in PBS for 1 h. Negative control were carried out by performing the same procedure with purified rabbit IgG at the concentration of 10 μg/ml. Cells were washed 3 times of 5 min each with PBS followed by incubation 30 min with biotinylated secondary antibody. Washed 3 times of 5 min each with PBS and then incubated 30 min with ABC reagent (VECTASTAIN Elite ABC Kit [rabbit IgG], Vector Labs, Burlingame, California). After washing, slides were incubated with ImmPACT DAB peroxidase substrate (Vector Labs). Reactions were terminated by washing twice with water and then counterstained with hematoxylin (Vector Labs).

siRNA silencing of CaSR and TRPA1. STC-1 cells were grown in 24-well culture plates and then transfected with 5 pmol/well of Silencer Select Predesigned siRNA targeted mCaSR (#1 and #2), mTRPA1 (#1 and #2) or nontargeting silencer negative control #1 siRNA using Lipofectamine RNAiMAX (Life Technologies, Grand Island, New York) according to the manufacturer’s protocol (Life Technologies, 2014). After transfection, cells were incubated for 48 h at 37°C. To verify that siRNA induced gene knockdown, total cellular RNA was isolated from cells 48 h posttransfection and subjected to qRT-PCR using TaqMan RNA-to-CT 1-step Kit (Life Technologies). The effects of siRNA silencing on DON-induced CCK release were determined after 48 h posttransfection.

Statistical analysis. All experiments were independently done in triplicate. Data were analyzed using Sigma Plot 11 Software (Systat Software, Inc, San Jose, California). Statistical comparisons between 2 groups were made using a Student’s t-test unless normality failed and a Mann-Whitney Rank Sum Test was executed. Multiple groups were analyzed for statistical significance using a 1-way analysis of variance (ANOVA) with Holm-Sidak multiple comparison procedure and when normality failed a Kruskal-Wallis 1-way ANOVA on Ranks with a Tukey comparison. All experiments were independently done in triplicate. Statistical analysis was performed using SigmaPlot 11 Software (Systat Software, San Jose, California). Statistical comparisons between 2 groups were made using a Student’s t-test unless normality failed and a Mann-Whitney Rank Sum Test was executed. Multiple groups were analyzed for statistical significance using a 1-way analysis of variance (ANOVA) with Holm-Sidak multiple comparison procedure and when normality failed a Kruskal-Wallis 1-way ANOVA on Ranks with a Tukey comparison.
Deoxynivalenol (DON) induces release of the gut hormones cholecystokinin (CCK) and glucagon-like peptide-1,7–36 amide (GLP-1) from STC-1 cells. A, B, DON-induced gut hormone release is concentration-dependent. STC-1 cells were treated with DON at indicated concentrations for 45 min. Medium was collected and CCK (A) and GLP-1 (B) concentrations determined by ELISA. Bars without the same letter are significantly different (P < .05). C, D, DON-induced hormone release is rapid. STC-1 cells were incubated with DON at 2 mM for indicated time intervals and CCK (C) and GLP-1 (D) measured. Lower case or upper case letters indicate significant difference within vehicle- or DON-treated groups, respectively. The # sign indicates significant difference between vehicle and corresponding DON-treated group at a given time point (P < .05). Results are representative of 3 independent experiments.

FIG. 1. Deoxynivalenol (DON) induces release of the gut hormones cholecystokinin (CCK) and glucagon-like peptide-1,7–36 amide (GLP-1) from STC-1 cells. A, B, DON-induced gut hormone release is concentration-dependent. STC-1 cells were treated with DON at indicated concentrations for 45 min. Medium was collected and CCK (A) and GLP-1 (B) concentrations determined by ELISA. Bars without the same letter are significantly different (P < .05). C, D, DON-induced hormone release is rapid. STC-1 cells were incubated with DON at 2 mM for indicated time intervals and CCK (C) and GLP-1 (D) measured. Lower case or upper case letters indicate significant difference within vehicle- or DON-treated groups, respectively. The # sign indicates significant difference between vehicle and corresponding DON-treated group at a given time point (P < .05). Results are representative of 3 independent experiments.

DON-Induced Concentration-Dependent Hormone Release Requires Regulation by GPCR CaSR

As suggested by the antagonist studies, confocal microscopy studies revealed that DON induced rapid (1–2 min) elevation of 

\[ \text{Ca}^{2+} \]

this GPCR appeared to mediate DON-induced elevation of 

\[ \text{Ca}^{2+} \].

DON-Induced \[ \text{Ca}^{2+} \] Increase Also Requires TRPA1

Thus, in STC-1 cells. The

Expression of CaSR by the STC-1 line was demonstrated by RT-PCR (Fig. 4A), Western analysis (Fig. 4B) and immunocytochemistry (Fig. 4C). Exposure of STC-1 cells to the allosteric CaSR agonist NPS 568 elicited a rapid increase in 

\[ \text{Ca}^{2+} \], that was ablated by preincubation with the allosteric antagonist NPS 2143 (Fig. 4D). Preincubation with CaSR antagonists NPS 2143 (Fig. 5A) and Calhex 231 (Fig. 5B) suppressed DON-mediated increases in cytosolic 

\[ \text{Ca}^{2+} \]. Accordingly, CaSR were confirmed to be expressed and functional in STC-1 cells and, furthermore, this GPCR appeared to mediate DON-induced elevation of 

\[ \text{Ca}^{2+} \].

CaSR-Driven \[ \text{Ca}^{2+} \] Increase and Hormone Release Requires TRPA1

Induction of 

\[ \text{Ca}^{2+} \], elevation in STC1 by the CaSR agonist NPS 568 was not only be suppressed by the CaSR antagonist NPS 2143 but also by the TRPA1 antagonists HC030031 and A967079 (Fig. 8). Thus, TRPA1 appeared to play a role downstream to CaSR in eliciting increased cytosolic 

\[ \text{Ca}^{2+} \] in STC-1 cells. The joint contributions of CaSR and TRPA1 in DON-induced hormone secretion were assessed in STC-1 cells using pharmacological antagonists. DON-induced CCK release was suppressed by the CaSR antagonists NPS 2143 and Calhex 231 as well as the TRPA1 antagonist HC 030031 (Fig. 9A–C). The combination of HC 030031 with either NPS 2143 or Calhex 231 additively inhibited DON-mediated CCK secretion. Similar results were observed relative to DON-induced GLP-1 secretion (Fig. 9B and 9D), again suggesting that CaSR and TRPA1 played complementary roles in these responses.
FIG. 2. DON-induced CCK and GLP-1 release in STC-1 cells depends on Ca\(^{2+}\) signaling and transient receptor potential melastatin-5 ion channel. A, B, STC-1 cells were preincubated for 15 min with: vehicle (DMSO); U73122 (10 \(\mu\)M), a phospholipase C inhibitor; 2-aminoethyl diphenyl-borinate (2-APB, 50 \(\mu\)M), an IP3 receptor antagonist; TPPO (10 \(\mu\)M), a selective inhibitor of TRPM5; nitrendipine (1 \(\mu\)M), an L-type voltage-sensitive Ca\(^{2+}\) channel (L-type VSCC) blocker; or EGTA (1 mM), a Ca\(^{2+}\) chelator. Cells were then incubated with DON (2 mM) for 30 min and supernatant fractions were analyzed for CCK (A) and GLP-1 (B). Different lower case and upper case letters indicate significant differences within control and DON-treated cells, respectively (\(P < 0.05\)). (C, D) STC-1 cells express TRPM5. Total RNA was isolated from STC-1 cells and subjected to RT-PCR (C). Estimated size of product (429 bp) is consistent with TRPM5 (indicated by arrow). Total protein of STC-1 cells was extracted and TRPM5 presence determined by Western analysis (D) (indicated by arrow).

FIG. 3. DON induces intracellular Ca\(^{2+}\) ([Ca\(^{2+}\)_\(i\)]) increase in STC-1 cells. A, DON dose-dependently induces [Ca\(^{2+}\)_\(i\)] elevation. STC-1 and HEK 293 cells were grown on matrigel-coated slides and then incubated 2 \(\mu\)M of Fluo-4, AM calcium indicator dye for 30 min, at room temperature in dark. After treatment with DON at indicated concentrations, Ca\(^{2+}\) influx was measured by confocal calcium imaging. Fluorescence intensities were recorded and mean value of the relative fluorescence change of 50 cells expressed as \(\Delta F/F\). B, C, Extracellular calcium modulates DON-evoked [Ca\(^{2+}\)_\(i\)] increase in STC-1 cells. STC-1 cells were preloaded with Fluo-4, AM as described earlier and exposed to 2 mM DON containing 0, 0.25, 2.5, or 5 mM CaCl\(_2\) (C) and \(\Delta F/F\) measured. All results are representative of 3 independent experiments.
CaSR- and TRPA1-Knockdown Impair DON-Induced CCK Release

The effects of CaSR- and TRPA1-specific siRNA knockdown on DON-induced CCK exocytosis were evaluated in STC-1 to confirm findings with pharmacologic antagonists. siRNA transfection caused ∼35% and 45% reductions in CASR mRNA (Fig. 10A) and TRPA1-mRNA (Fig. 10B) expression levels, respectively, as compared with the vehicle-transfected cells. Transfections with CaSR siRNAs (Fig. 10C) or with TRPA1 siRNAs (Fig. 10D) significantly attenuated DON-stimulated CCK release in STC-1 cells. Furthermore, DON-induced CCK release was identical in cells transfected with negative control siRNAs to those transfected only with vehicle (Fig. 10A and 10D). Thus, siRNA knockdown confirmed the antagonist studies, again suggesting that CaSR and TRPA1 were both involved in DON-induced CCK secretion.

DISCUSSION

Prior investigations in the mouse have suggested that DON-induced food refusal is mediated by hormones known to be produced by EECs (Flannery et al., 2012; Wu et al., 2014). Here, we employed the murine STC-1 model to elucidate the upstream mechanisms by which DON elicits EEC hormone secretion. The results indicate for the first time that DON induces Ca²⁺-dependent secretion of CCK and GLP-1. These hormones regulate food intake and energy homeostasis and are products of 2 critical EEC populations—l cells of the small intestine and L cells of the large intestine, respectively. Although this cell line expresses PYY mRNA, it did not robustly secrete the PYY₃₋₃₆ in response to known STC-1 inducers or to DON (data not shown). As summarized in Figure 11, the data presented herein suggest that DON...
induces \([Ca^{2+}]_i\) elevation in STC-1 cells via a CaSR-mediated pathway that involved the following serial events: (1) PLC-mediated activation of the IP3 receptor and mobilization of intracellular \(Ca^{2+}\) stores, (2) activation of the TRPM5 Na\(^{2+}\) channel and resultant L-type VSCC-facilitated extracellular \(Ca^{2+}\) entry, and (3) amplification of extracellular \(Ca^{2+}\) entry by TRPA1 activation. It is further predicted that this elevation in \([Ca^{2+}]_i\) subsequently elicits secretion of CCK and GLP-1.

Consistent with our findings, STC-1 has been previously shown to respond to agonists and antagonists of CaSR, TRPM5, and TRPA1 (Hira et al., 2008; Kurogi et al., 2012; Nakajima et al., 2012; Purhonen et al., 2008; Shah et al., 2012). CaSR regulates serum calcium homeostasis and is directly activated by sensing increased extracellular \(Ca^{2+}\), other inorganic cations and...
organic polycations; however, this receptor has many other physiological roles (Chakravarti et al., 2012; Ward et al., 2012). Importantly, it has been postulated that CaSR functions as a chemosensor of intestinal luminal content and that its activation can elicit secretion of gut hormones which regulate nutritional homeostasis (Liou et al., 2011; Nakajima et al., 2012). Consistent with this role, in the presence of Ca²⁺, CaSR is activated by various aromatic L-amino acids, dietary peptides,
polyamines, and fatty acids that are encountered in the gut after meal consumption. Our results suggest that DON hijacks these normal physiologic processes by acting on CaSR, thereby disrupting homeostasis and causing aberrant loss of appetite. It is possible that the toxin allosterically interacts with CaSR but this will require further study.

TRPM5 is a Ca\(^{2+}\)-activated cation channel that mediates signaling in taste and other chemosensory cells (Huang and Roper, 2010). This TRP channel is distributed in chemosensory cells located throughout the digestive tract, in the respiratory system and in the olfactory system (Liman, 2007). TRPM5 is the final element in a signaling cascade that starts with the activation of GPCRs by bitter, sweet, or umami taste molecules and that requires PLC\(_{gi}\) (Kaske et al., 2007). Consistent with our model, this latter enzyme catalyzes the conversion of PIP\(_2\) into DAG and IP\(_3\), and the ensuing release of Ca\(^{2+}\) from intracellular stores activates TRPM5.

It is well known that TRPA1 is expressed in neurons and mediates pain and neurogenic inflammation in response to heat, cold, mechanical, and chemical stressors (Nilius et al., 2012). However, its expression and role in nonneuronal cell types that control diverse physiological functions is now being recognized as important (Fernandes et al., 2012). The finding that DON mediates increased [Ca\(^{2+}\)], in part, via TRPA1, was surprising because in its role as a chemosensor, TRPA1 is primarily activated by reactive chemicals such as allyl isothiocyanate (AITC), cinnamaldehyde, formalin, hydrogen peroxide, 4-hydroxynonenal, and acrolein. Although DON contains an epoxide group, this moiety is shielded by the parent ring thus masking and preventing it from reacting with other chemicals or macromolecules. As an alternative, it has been proposed that TRPA1 and other TRP channels are activated through intracellular signaling involving: (1) GPCR-mediated activation via PLC and diacylglycerol (DAG)-dependent mechanisms, (2) intracellular phosphatidylinositol phosphates (eg, PIP\(_2\)), (3) elevated [Ca\(^{2+}\)], and (4) membrane depolarization (Nilius et al., 2012).

Thus, it is reasonable to suggest that TRPA1 activation results from DON-induced CaSR activation (Fig. 11) rather than as a result of direct interaction between the toxin and this TRP channel. Nevertheless, a few nonreactive activators (eg, nicotine, PF-4840154) have been reported to activate TRPA1, so without further investigation it is not yet possible to exclude the possibility of a direct interaction with DON.

We recognize that a limitation of this study was that the high DON concentrations employed might possibly be associated with other toxic effects upon prolonged incubation (Maresca, 2013) such as apoptosis as has been observed in the RAW 264.7 macrophage cell line incubation with 1 \(\mu\)M DON for 6 h (Zhou et al., 2005). Because our primary focus was to determine DON’s short term (15–45 min) effects (ie, intracellular calcium increase and hormone secretion) in this enteroendocrine model that would be indicative of a rapid intestinal chemical defense response (eg, food refusal, reduced gut motility, and emesis), we confirmed viability during this time period but did not measure the effects on viability of \(\geq\)6 h incubation at these concentrations. Although concentrations of DON required to evoke Ca\(^{2+}\) and hormone responses in STC-1 (\(\geq500\) \(\mu\)M) were very similar to those of other agonists that induce hormone secretion in this model (Hira et al., 2012), comparatively lower DON gut luminal and tissue concentrations (\(\geq10\) \(\mu\)M) might be expected to elicit satiety hormone elevations and anorectic responses in the mouse (Flannery et al., 2012). This divergence might reflect several inherent limitations associated with using the cloned STC-1 line to predict the effects of EEC lineages in vivo. First, the dissociated state of these cells and absence of adjacent (ie, epithelial, Paneth, goblet) or supporting cells might affect their ability to respond identically to the in vivo setting. Second, the responsiveness might be affected by the absence of basal luminal components such as nutrients (eg, amino acids, fatty acids) and microbiota found naturally in the gut that might...
have modulatory effects on EEC. Finally, because STC-1 is a cancer cell line, there is the clear potential for expression of drug transporters such as the ABC and MDR families (Choi and Yu, 2014; Kathawala et al., 2014) which have been demonstrated to affect DON uptake (Videmann et al., 2007). Nevertheless, the STC-1 model provides a useful starting point for future investigations of GPCR- and TRP-related mechanisms in ex vivo and in vivo models.

Taken together, the results of this investigation indicate that DON evokes CCK and GLP-1 secretion in the STC-1 EEC model by activating CaSR- and TRPA1-mediated Ca\(^{2+}\) signaling pathways (Fig.11). A potential outcome of this research is that understanding the cellular and molecular mechanisms for DON's anorectic effects will facilitate design of new strategies for preventing these effects in humans and animals as well as lead to new in vitro assays to identify, classify and measure toxic potencies of trichothecene congeners/metabolites that target EEC. The capacity for DON to evoke aberrant secretion of satiety hormones is of further interest because of their recognized pathophysiological involvement in irritable bowel syndrome (Zhang et al., 2008), eating disorders (Chaudhri et al., 2006) and failure to thrive in the elderly (Hays and Roberts, 2006). Over the long term, it is anticipated that this research will serve as a template for future exploration into the role of different EEC lineages in the body, it is anticipated that this research will serve as a template for future exploration into the role of different EEC lineages in the body.

SUPPLEMENTARY DATA

Supplementary data are available online at http://toxsci.oxfordjournals.org/.

FUNDING

This study was supported by USDA Wheat and Barley SCAB Initiative Award (Grant Number 59-0206-9-058); USDA NIFA Award (Grant Number 2011-0635); and by the National Institute for Environmental Health (Grant Number ES3358).

ACKNOWLEDGMENTS

The authors thank Dr Melinda Frame form the MSU Center for Advanced Microscopy for technical advice and Mary Rosner for assistance with manuscript preparation.

REFERENCES


Flannery, B. M., Clark, E. S., and Pestka, J. J. (2012). Anorexia induction by the trichothece deoxynivalenol (vomitoxin) is mediated by the release of the gut satiety hormone peptide YY. Toxicol. Sci. 130, 289–297.


Cellular Signaling Cascades Liedtke WB, Heller S, Eds., Taylor & Francis Group, LLC, Boca Raton FL.


